Bacillus Calmette-Guérin (BCG) shortages and the fragile BCG supply chain have created a bladder cancer treatment vacuum.

The FDA has expanded the approval of Winrevair to include treatment of adults with PAH WHO Group 1 to improve exercise capacity and WHO FC, and reduce the risk of clinical worsening events including ...

The phase 3 ALBAN trial tested atezolizumab plus BCG in BCG-naïve patients with high-risk, non-muscle-invasive bladder cancer (NMIBC).

PlGF cutoff <100 pg/mL demonstrated 100 percent sensitivity and specificity at 20 to 24 weeks of gestation for early-onset preeclampsia.

(HealthDay News) — Primary care physicians (PCPs) spend an average of 61.8 hours per week caring for a patient panel, according to a study published online Oct. 21 in the Annals of Internal Medicine.

ASN’s Kidney Week 2025 is happening November 5-9, 2025 at the George R. Brown Convention Center in Houston, Texas.

(HealthDay News) — Macrovascular infiltration and spikes in circulating tumor cell (CTC) clusters are associated with cancer mortality, according to a study published online Oct. 16 in Nature Medicine ...

(HealthDay News) — More than one in five young adults report using cannabis or alcohol to get to sleep, according to a research letter published online Oct. 13 in JAMA Pediatrics.

Smaller declines seen in early-stage cancer diagnosis during COVID-19 pandemic in adults aged 18 to 44 years, men, those with high comorbidity burden.

The phase 3 POTOMAC trial tested durvalumab added to BCG in patients with high-risk non-muscle-invasive bladder cancer (NMIBC).

Adding durvalumab to induction and maintenance with Bacillus Calmette–Guérin (BCG) can improve disease-free survival in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer, data ...

Prevalence increased to 68.6 percent with new criteria, which include anthropometric measures such as waist circumference, waist-to-hip ratio, waist-to-height ratio.